Currently, molecular targeted drugs, targeting the inhibition of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), platelet derived factor receptor (PDGFR) and so on, shed light on the treatment of ovarian cancer [7, 8]. The gene discussed is EGFR; the disease is ovarian carcinoma.